Further evidence for the contribution of TLR signaling to the development of sporadic cancer, and colitis-associated cancer, stemmed from the use of TLR4-deficient mice that were protected against tumorigenesis following azoxymethane (AOM) and DSS treatment (145). This evidence concerns the gene TLR4 and cancer.